Indoco Remedies Gains EU GMP Certification for Baddi Plant from Malta Medicines Authority

Indoco Remedies has cleared a significant compliance threshold for European market access, with the Malta Medicines Authority issuing EU GMP certification to its Baddi manufacturing facility following a five-day on-site inspection. For QA directors managing multi-market compliance portfolios, the certification signals that Indian solid-dose and formulation sites can satisfy the EU's inspection-led approval pathway when documentation, process controls, and facility readiness are aligned.

The Malta Medicines Authority conducted the inspection between 29 January and 3 February 2026, with the GMP certificate issued thereafter. Malta, as an EU member state, operates under the European Medicines Agency's mutual recognition framework, meaning the certificate carries regulatory weight across all 27 EU member states. Facilities seeking this designation must demonstrate conformance with EudraLex Volume 4 GMP guidelines, covering quality systems, personnel, premises, documentation, and production controls broadly consistent with ICH Q10 principles.

The Baddi site, located in Himachal Pradesh, is one of Indoco Remedies' primary export-facing manufacturing units. Achieving EU GMP status at Baddi expands the company's ability to supply European markets directly and positions the facility for potential contract manufacturing discussions with EU-based marketing authorisation holders. For plant heads overseeing similar India-based operations, the inspection window, five consecutive working days, reflects the depth of review EU inspectors apply to site master files, batch records, validation dossiers, and quality management systems.

The certification also carries implications for Indoco's regulatory affairs function. Maintaining EU GMP status requires ongoing compliance with EudraLex Volume 4 requirements, including timely submission of variations, annual product quality reviews, and proactive CAPA management. Any post-certification deviation that triggers a regulatory action could affect the facility's standing across all EU markets simultaneously, given the cross-border validity of the certificate.

The Baddi certification adds to a growing list of Indian manufacturing sites that have navigated the EU's inspection pathway, a process that demands considerably more pre-inspection preparation than domestic regulatory submissions alone require.

Source: Media4Growth via Indian Pharma Post, 14 May 2026.